Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial by Palfi, Stéphane, Prof, Gurruchaga, Jean Marc, MD, Ralph, G Scott, PhD, Lepetit, Helene, PhD, Lavisse, Sonia, PhD, Buttery, Philip C, PhD, Watts, Colin, PhD, Miskin, James, PhD, Kelleher, Michelle, PhD, Deeley, Sarah, MSc, Iwamuro, Hirokazu, MD, Lefaucheur, Jean Pascal, MD, Thiriez, Claire, MD, Fenelon, Gilles, MD, Lucas, Cherry, BA, Brugières, Pierre, MD, Gabriel, Inanna, MD, Abhay, Kou, MD, Drouot, Xavier, MD, Tani, Naoki, MD, Kas, Aurelie, MD, Ghaleh, Bijan, Prof, Le Corvoisier, Philippe, MD, Dolphin, Patrice, MSc, Breen, David P, MRCP, Mason, Sarah, BSc, Guzman, Natalie Valle, MSc, Mazarakis, Nicholas D, Prof, Radcliffe, Pippa A, PhD, Harrop, Richard, PhD, Kingsman, Susan M, PhD, Rascol, Olivier, Prof, Naylor, Stuart, PhD, Barker, Roger A, Prof, Hantraye, Philippe, PhD, Remy, Philippe, Prof, Cesaro, Pierre, Prof, Mitrophanous, Kyriacos A, PhD

Get full text